An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient Program
NCT06782789 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 96
Last updated 2025-01-20
Summary
The study is pilot, observational, retrospective, Italian multicenter study.
Conditions
- Diffuse Large B Cell Lymphoma (DLBCL)
Sponsors & Collaborators
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna
lead OTHER
Principal Investigators
-
Pier Luigi Zinzani, MD · IRCCS Azienda Ospedaliero-Universitaria di Bologna
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-03-01
- Primary Completion
- 2026-08-31
- Completion
- 2026-08-31
Countries
- Italy
Study Locations
More Related Trials
-
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT06521255 ·Status: RECRUITING ·Phase: PHASE3
-
Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma
NCT01369784 ·Status: COMPLETED
-
An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme
NCT06734078 ·Status: ACTIVE_NOT_RECRUITING
-
Italian Multicenter Retrospective Observational Study on Transformed Lymphomas
NCT02927756 ·Status: UNKNOWN
-
Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)
NCT06299553 ·Status: RECRUITING
-
A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)
NCT06835530 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients
NCT05222555 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
NCT06760156 ·Status: RECRUITING ·Phase: PHASE2
-
Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting as Indolent Lymphoma
NCT06822829 ·Status: RECRUITING
-
Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma
NCT00799513 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab
NCT05267054 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Observational Controlled Clinical Trials, on Adult Patients With T-lymphoblastic Lymphoma Treated With Intensive Chemo/Radiotherapy or Intensive Chemotherapy Followed by Transplant. Evaluation of Clinical, Anatomy -Pathological Parameters
NCT00882011 ·Status: UNKNOWN
-
Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies
NCT05541341 ·Status: RECRUITING
-
Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure
NCT06918912 ·Status: RECRUITING ·Phase: PHASE2
-
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
NCT05182957 ·Status: RECRUITING ·Phase: PHASE2
-
Indolent Non Follicular Lymphomas Prognostic Project
NCT02904577 ·Status: COMPLETED
-
Lenalidomide Monotherapy in R/R DLBCL
NCT04150328 ·Status: COMPLETED
-
Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's
NCT02371148 ·Status: COMPLETED ·Phase: PHASE2
-
Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma
NCT04433182 ·Status: TERMINATED ·Phase: PHASE2
-
A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL
NCT05883709 ·Status: UNKNOWN
-
A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma
NCT01766583 ·Status: COMPLETED ·Phase: PHASE1
-
Retrospective Observational Study of Italian Cohort of Lymphoma Patients (RETRO-LYMPH)
NCT06781437 ·Status: RECRUITING
-
The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study
NCT07240194 ·Status: RECRUITING ·Phase: PHASE2
-
Italian Study of Patients With Lymphoma
NCT06814925 ·Status: RECRUITING
-
Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma
NCT00556127 ·Status: COMPLETED ·Phase: PHASE2